|
Market Closed -
NSE India S.E.
15:05:10 18/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,837.30 INR | -1.61% |
|
-1.27% | +6.84% |
| 09-09 | Sun Pharma Sets Up Global Treasury Center in India's GIFT City | MT |
| 09-09 | Sun Pharma Assigned Baa1, BBB+ Ratings by Moody's, S&P | MT |
| Market Cap | 4,408B 45.94B 40.06B 37.83B 34.35B 64.36B 64.63B 453B 175B 2,241B 173B 169B 7,211B | P/E 2027 * |
33.9x | P/E 2028 * | 28.7x |
|---|---|---|---|---|---|
| Enterprise Value | 4,138B 43.12B 37.6B 35.5B 32.24B 60.41B 60.66B 425B 164B 2,104B 162B 158B 6,769B | EV / Sales 2027 * |
6.35x | EV / Sales 2028 * | 5.58x |
| Free-Float |
44.39% | Yield 2027 * |
0.93% | Yield 2028 * | 1.09% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -1.61% | ||
| 1 week | -1.27% | ||
| Current month | -7.43% | ||
| 1 month | -2.38% | ||
| 3 months | +0.93% | ||
| 6 months | +2.39% | ||
| Current year | +6.84% |
| 1 week | 1,828 |  | 1,877.2 |
| 1 month | 1,828 | | 1,984.8 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.61% | -1.27% | +13.40% | +59.79% | 46.78B | |
| -1.02% | -3.01% | +36.66% | +100.50% | 37.88B | |
| +2.19% | +3.78% | +12.21% | +79.75% | 11.82B | |
| +1.32% | +1.54% | -10.59% | +12.87% | 11.61B | |
| -0.95% | -0.38% | +17.65% | +146.45% | 9.12B | |
| +0.39% | +2.72% | +29.99% | +39.46% | 7.38B | |
| +1.30% | +1.34% | +19.83% | +185.74% | 7.12B | |
| -0.06% | +1.94% | +39.71% | -18.67% | 7.21B | |
| +0.70% | -2.06% | -42.22% | +7.42% | 4.99B | |
| +1.80% | +1.24% | +39.15% | +108.26% | 4.57B | |
| Average | +0.41% | +0.35% | +15.58% | +72.16% | 14.85B | |
| Weighted average by Cap. | -0.39% | -0.11% | +18.96% | +74.38% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.79B 5.92B 5.59B 5.07B 9.51B 9.55B 66.93B 25.83B 331B 25.49B 24.92B 1,065B | 730B 7.6B 6.63B 6.26B 5.68B 10.65B 10.69B 74.98B 28.94B 371B 28.56B 27.93B 1,193B |
| Net income | 129B 1.35B 1.18B 1.11B 1.01B 1.89B 1.9B 13.3B 5.13B 65.77B 5.06B 4.95B 212B | 154B 1.6B 1.4B 1.32B 1.2B 2.24B 2.25B 15.79B 6.09B 78.08B 6.01B 5.88B 251B |
| Net Debt | -271B -2.82B -2.46B -2.32B -2.11B -3.95B -3.97B -27.82B -10.74B -138B -10.6B -10.36B -443B | -338B -3.53B -3.08B -2.9B -2.64B -4.94B -4.96B -34.78B -13.42B -172B -13.25B -12.95B -554B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/09/26 | ₹1,837.30 | -1.61% | 2,896,860 |
| 17/09/26 | ₹1,867.30 | +0.74% | 1,377,506 |
| 16/09/26 | ₹1,853.50 | +1.01% | 1,370,607 |
| 15/09/26 | ₹1,835.00 | -0.27% | 1,437,151 |
| 11/09/26 | ₹1,840.00 | -1.13% | 1,445,071 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
